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Abstract
This article gives an overview of the ethical issues in nutrigenomics re-
search and personalized nutrition. The principles of research ethics, i.e.,
autonomy, beneficence, nonmalfeasance, and justice, are challenged by
rapidly growing cross-border research activities utilizing existing and
upcoming biobanks for studies of the interaction of genes with diet
on risk of common diseases. We highlight the ethical issues, some un-
resolved, in international collaborative projects of which researchers
should be aware. Personalized nutrition (tailoring diet on the basis of
genotype) is one possible application of nutrigenomics research. How-
ever, until the scientific evidence concerning diet–gene interactions is
much more robust, the provision of personalized dietary advice on the
basis of specific genotype remains questionable. From the ethical and
social perspective, nutrigenomics offers significant opportunities to im-
prove public health by enhancing understanding of the mechanisms
through which diet can be used to reduce the risk of common polygenic
diseases.
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NUTRIGENOMICS—
INTRODUCTION TO
THE CONCEPT
Although it has been known for decades
that certain nutrients can modify gene ex-
pression (78), high-throughput, postgenomic
technologies—which twenty-first-century ad-
vances have made available for studying interac-
tions between nutrition and the genome—have
the potential to revolutionize the understand-
ing of links between food and health. This is the
niche occupied by the emergent science of nu-
tritional genomics (nutrigenomics), which aims
to reveal the intimate inter-relationships be-
tween nutrition and the genome and to provide
the scientific basis for improved public health
through dietary means.
As illustrated in Figure 1, individual genetic
makeup influences nutritional needs and may
modify dietary choices (111). In addition, the
nature and amounts of foods influence gene ex-
pression at all levels of regulation, including
via altered epigenomic markings (56). Genome-
wide association studies are producing power-
ful evidence for links between (novel) genetic
loci and risk of common human diseases (103,
121). However, since diet and other lifestyle
factors are major determinants of these same
diseases (125), it is highly likely that interac-
tions between genotype and diet are impor-
tant in determining the risk of most (if not all)
common complex diseases. Proof of principle
for this hypothesis has been provided by obser-
vational nutritional genetics studies where the
outcome measures have been markers of dis-
ease risk, most notably cardiovascular disease
(91). However, deoxyribonucleic acid (DNA)
(and other biological material) in biobanks from
cohort (and other) studies investigating rela-
tionships between dietary exposure and health
outcomes provides a rich resource for novel
studies of diet–gene interactions (72). Such
studies are particularly powerful when the
studies are large, dietary exposure (and other
lifestyle factors) is characterized robustly, and
there are hard end points such as diagnosis of
disease or death from known causes. This has
encouraged the development of consortia that
cross national and continental borders to facil-
itate the pooling of resources, including bio-
logical samples and data as exemplified by the
National Cancer Institute Breast and Prostate
Cancer Cohort Consortium (22).
To date, most studies have been relatively
small scale, have focused on individual genes
448 Bergmann · Go¨rman · Mathers
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Figure 1
Conceptual model of interactions between nutrition and the genome underlying links between food and health. The science of
nutrigenomics uses high throughput, postgenomics technologies to investigate these interactions.
(or haplotypes) and single nutrients, and have
not addressed the complexity inherent in in-
teractions between multiple genetic and mul-
tiple dietary factors (77). To determine causal-
ity, an extensive program of human intervention
studies is needed, and its design should include
prospective genotyping of volunteers (82) to
maximize the likelihood of obtaining unequiv-
ocal results.
Until recently, much of the application
of postgenomic technologies to understand-
ing mechanistic interactions between nutrition
and cell or tissue function and health has been
devoted to studies in cells or model organ-
isms. Given the costs of some of these tech-
nologies, the need to build expertise in their
use, and the greater practical difficulties of hu-
man studies, this prioritization is understand-
able. However, over the past couple of years
there has been a welcome emergence of nu-
trigenomics studies undertaken in human vol-
unteers. Eady et al. (27) investigated the extent
of, and factors responsible for, intra- and in-
terindividual variation in transcription profiles
for approximately 14,000 genes in peripheral
blood mononuclear cells; this work provides
important information for the design of future
studies. In an examination of responses to eat-
ing breakfast (which included acetaminophen),
van Erk et al. (114) observed 954 differentially
expressed genes in blood, with approximately
three times as many genes differentially ex-
pressed after a high-protein meal than after a
high-carbohydrate meal. Obtaining samples of
tissue other than blood cells is often an im-
pediment in human studies, but Polley et al.
(93) demonstrated that it is possible to investi-
gate the proteome of the human colorectal mu-
cosa using biopsy samples and to identify po-
tential novel biomarkers of bowel cancer risk.
In principle, metabolomic studies on easily ac-
cessible biofluids (e.g., plasma, urine, and saliva)
could be incorporated readily into conventional
nutrition study designs and so provide an op-
portunity to investigate the effect of the nutri-
tional regime on a wide range of metabolites;
such studies could greatly enhance understand-
ing of the impact of the intervention. Walsh
et al. (116) reported considerable inter- and
intraindividual variation in metabolite profiles
and concluded that the urinary metabolome
provided a much better reflection of acute food
intake than did plasma or saliva.
There is now significant international mo-
mentum behind the development and exploita-
tion of nutrigenomics approaches for both
www.annualreviews.org • Ethics of Nutrigenomics 449
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NuGO: European
Nutrigenomics
Organisation
public and personal health (35, 57, 60, 84). This
reinvigoration of nutrition research brings with
it many challenges in terms of study design and
ethics, and the latter is the subject of the re-
mainder of this review.
HUMAN NUTRIGENOMICS
RESEARCH—ETHICAL
CONSIDERATIONS
Underlying Ethical Principles
In principle, human studies in nutrigenomics
research do not have unique ethical issues. They
are subject to the same basic ethical principles
that apply to studies in biomedical or phar-
macogenetics research. The four principles of
protection of a research participant are auton-
omy (self-determination), beneficence (maxi-
mal benefit), nonmalfeasance (minimal harm),
and justice (distribution of benefits and harms
across groups in society) (85, 89, 127). These
principles focused on experimental studies in
which participants were subject to some form of
intervention with less attention to issues arising
in observational studies since the latter are per-
ceived to have minimal harm because there is
no intervention that can cause physical or psy-
chological damage.
New Ethical Principles for a
New Field in Nutritional Science?
The two aspects of nutrigenomics science that
have challenged the traditional ethics of human
research are the generation of genetic informa-
tion and the conduct of large-scale population-
based studies. The likely benefits in terms of
improved health care or disease prevention that
can be expected from (nutri)genomics research
are, as yet, unclear (24). As such, participants
in nutrigenomics research projects contribute
to the generation of new information that, un-
like clinical research, is unlikely to benefit the
participating individuals (59). Therefore, soci-
etal values such as solidarity, public participa-
tion, and trust are emerging ethical principles
in contemporary (nutrigenomics) research (12,
14, 66, 67). Reaching this balance is not possible
with a static set of legal and ethical frameworks
and needs continuing communication between
researchers, research participants, politicians,
ethicists, and lawyers with the aim of reaching
the highest degree of consensus (67). For the
field of nutrigenomics research, the European
Nutrigenomics Organisation (NuGO) there-
fore has developed guidelines designed to as-
sist researchers undertaking human nutrige-
nomics studies including biobank research
(8, 34). The NuGO Bioethical Guidelines are
based on officially published documents for
which international agreement was achieved
(19, 20) or that have been subject to thorough
discussions among experts (39). The NuGO
guidelines are available in an interactive In-
ternet environment to allow researchers, ethics
committees, and other stakeholders to use them
and to provide feedback about their utility (34).
Informed Consent
for Genomic Research
Ethical aspects of genotypic informa-
tion. The independent expert group of the
European Commission (EC) defined various
perceptions influencing the debate about ge-
netic testing (32). Two distinctly different per-
ceptions can be identified. Genetic exceptional-
ism emphasizes the features of DNA-sequence
information that distinguish it from other in-
formation because it identifies family relation-
ships unequivocally, can be obtained from small
amounts of biological material, may be used to
predict future health events, may be of interest
to third parties such as insurers, employers, or
potential spouses, and can be recovered from
stored specimens in the future (88, 98). The al-
ternate position taken by the EC expert group
is that “[g]enetic information is part of the en-
tire spectrum of all health information and does
not represent a separate category as such. All
medical data, including genetic data, must be
afforded equally high standards of quality and
confidentiality at all times” (33). Public percep-
tions appear to favor genetic exceptionalism.
The development of DNA fingerprinting for
450 Bergmann · Go¨rman · Mathers
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forensic purposes, for paternity tests, and for
detection of mutations responsible for mono-
genic disorders such as Huntington’s disease or
Tay-Sachs disease has contributed to the be-
lief that genes constitute a person’s identity or
even destiny (88). This perception has to be ad-
dressed in the process of informing and obtain-
ing consent of participants in nutrigenomics
studies. An ethics committee evaluating a pro-
posal for a nutrigenomics study may focus on
genetic screening and disclosure of test results.
International guidelines recognize the duty to
disclose genotypic test results to research par-
ticipant on the basis of the fundamental right
to know (or not to know). However, partic-
ularly in the case of nutrigenomics research,
where the consequences of particular genotypes
may be unknown, such information may be pro-
vided on a group basis. Knoppers et al. (68) give
a comprehensive overview of existing interna-
tional guidelines on this issue. At the individual
level, the World Health Organization (WHO)
proposed disclosure of genetic information pro-
vided there is a clear clinical (health) benefit, as
this will avert or minimize significant harm to
the individual (provided there is no indication
that the research participant would prefer not
to know) (126).
The process of information and consent-
ing. Several authors (9, 26, 73) have pointed
out that the researcher responsible for commu-
nication with the research participant must be
sensitive to the participant’s level of compre-
hension and use appropriate communication
approaches. However, too much information
can confuse and may increase the misconcep-
tion of the participant. Eriksson & Helgesson
(29) suggest a tool that identifies research par-
ticipants who want only limited information.
Currently, the system of informed consent fo-
cuses on the form to be signed by the partici-
pant; too little attention is paid to its role as a
means for communication and education. The
forms are perceived as a contract that protects
the researchers and their institution (6) and tend
to neglect the role of research participants as
partners in the study (43). In this regard, the
measures that take place when consent is with-
WHO: World Health
Organization
drawn need to be communicated clearly. Al-
though the participant has the right to request
the obliteration of the sample and data, it is ac-
ceptable to anonymize by stripping all identi-
fiers (unlinking). This is particularly important
for prospective studies such as cohort studies,
intervention trials, and biobank research be-
cause obliteration of samples and data may bias
the results of the study and thus challenge their
generalizability. In consequence, the interests
of the sustaining participants and the public
may be jeopardized. Issues of practicability also
exist, especially in international studies, where
samples and data may have been exchanged with
other institutions. Retaining samples and data
unlinked and anonymized would balance indi-
vidual and societal interest (12, 30, 39).
In some cases, there may be a conflict be-
tween undertaking a methodologically unbi-
ased study and giving the study participant
full information. This is particularly difficult
in studies with a dietary intervention because
control persons may alter their intake of the
food that is the subject of the hypothesis (73).
In such cases, it may be ethically appropriate
not to disclose the underlying hypotheses be-
cause research of a high standard is also of eth-
ical value.
Benefits and Risks
Most nutrigenomics studies are likely to benefit
society rather than the individual. Risks for the
individual usually concern the confidentiality of
medical, genetic, and other data and implica-
tions of potential dissemination of study results.
In addition, benefit-risk assessments should
consider the inconvenience associated with an-
swering detailed questions on diet, health, and
lifestyle and the potential discomfort involved
in sample collection or caused by the interven-
tion procedures (73). It has been assumed that
altruism is the main motive of those participat-
ing in nutrigenomics studies, but Merz et al.
(83) have pointed out that this fails to recognize
the complex, sometimes competing, interests
of individuals, researchers, public and private
scientific institutions, financiers, and industry.
Although better public health is the long-term
www.annualreviews.org • Ethics of Nutrigenomics 451
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common goal for all or most of the stakehold-
ers in nutrigenomics studies, the internationally
inconsistent legal status of the biological sam-
ples (parts of the body that cannot be sold or
property that is conveyed by property rights),
which are normally donated by study partici-
pants, makes it difficult to give ethical guidance
on benefit sharing (12). The ethical aspects of
commercialization of nutrigenomics research
are currently under discussion (12, 15, 58, 83).
Biobanks in Nutrigenomics
Definition. A biobank is a repository of col-
lected bodily substances or DNA often link-
able to data on health or lifestyle of the
donor (12, 28, 39). Related terms include gene
bank, genetic biobank, DNA bank, or genetic
database (14, 63). Large population-based gene
banks such as DeCode (from Iceland), the
BioBank UK, the Estonian Genome Project,
or the Genome Database of the Latvian Popu-
lation may be distinguished from other types
of biobanks because they have made explicit
from the outset that their purpose included
population-based genetic research into the eti-
ology of diseases. In the absence of a partic-
ular regulation for biobanks, biological ma-
terial (samples) is considered as part of the
human body, resulting in legal implications
such as property status, whereas the linkable
database associated with these samples is usu-
ally covered by data protection legislation.
Therefore, in countries with large population-
based biobanks, particular legal frameworks
have been established that regulate both ethical
and legal aspects of their operation (2, 3, 10, 50,
53, 54). Where such a regulatory framework is
available, other types of biobanks are likely to
fall under these acts. Other types of biobanks
include smaller collections of samples and data
from single studies or derived within a clinical
context that are stored in a systematic manner
and may be linked to health relevant data.
Ethical guidance for biobank-related re-
search. The absence of an agreed international
ethical and legal framework for biobank-related
research poses a significant ethical challenge
(12, 28). The national and international claims
for more openness of biobanks for genomics re-
search challenge the traditional legal and ethi-
cal framework for biomedical research and have
implications for nutrigenomics research. How-
ever, most of the legally binding acts governing
biobanks operate at national levels and are in-
appropriate for regulating international coop-
eration. Therefore, over the past 34 years, vari-
ous international organizations have developed
guidelines, most of which have no legal impli-
cation and are intended to define best practice
(12). However, in practice, the validity and fea-
sibility of the guidelines have been challenged
because they neither explain why it is ethical to
act in a certain way nor offer concrete practical
guidance (31). As a consequence, international
organizations such as the United Nations Ed-
ucational, Scientific and Cultural Organization
(113), WHO (123), Human Genome Organisa-
tion (52), and World Medical Association (128)
have released guidelines that should guarantee
biobank research activities are undertaken ac-
cording to generally accepted ethical standards.
Further guidelines for human genetic research
databases are expected shortly from the Organ-
isation for Economic Co-operation and Devel-
opment. However, disputes about a variety of
core issues of biobank research remain. These
include:
¥ the legal status of stored biological mate-
rial including DNA;
¥ the possibility of withdrawal of the con-
sent at any time;
¥ the consequences of withdrawal of con-
sent;
¥ the obligation to inform subjects of iden-
tifiable samples for whom an increased
disease risk was detected;
¥ the access to the samples or genetic data
by relatives after the death of the research
participant;
¥ the participation of vulnerable subjects
(such as children or incapacitated adults);
¥ the sharing of profits that might arise
from commercial products that are devel-
oped using the samples;
452 Bergmann · Go¨rman · Mathers
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¥ the ethical implications of anonymization
of samples and data by irreversibly strip-
ping all identifiers;
¥ the circumstances under which subjects
should be recontacted to renew consent
for the use of the sample in another re-
search project and the situation in which
consent could be waived;
¥ the definition of risks and benefits from
genetic-based biobank research.
Recently, the German National Ethics
Council (NER) released an “innovative and
progressive opinion” (65) that includes a joint
declaration by NER and the French National
Consultative Committee on Ethical Issues (39).
Their position is particularly progressive re-
garding the consent issue because waiver of
consent (for existing sample collections) and
broad consent (for upcoming biobanks) are eth-
ically justifiable when accompanied by substan-
tive protection by ethical review boards and
oversight by data protection officers (39). In this
way, anonymization of samples and ethical im-
plications can be avoided. In contrast, in the
United States and Canada, the most frequently
recommended model is a multilayered con-
sent, where the research participant can make
choices to limit consent for the use of samples
to the primary project only or to certain kinds
of research in the future (9, 26, 28, 109). This
may impair research not only at a practical level
but also at a methodological level by risking the
introduction of bias, because some ethnic or re-
ligious groups are more likely not to consent
to future use of samples and data for particu-
lar types of research (1, 16, 45, 105). This may
create an ethical issue at the societal level (14).
Ethics in international cooperation. Nu-
trigenomics research usually requires infor-
mation on diet or nutritional status in addi-
tion to genetic and health-related data. Where
the focus is on diet–gene interactions in
population-based studies, larger numbers of
subjects add power so there is considerable util-
ity in combining samples and data from sev-
eral (international) cohorts. To promote such
collaboration, the umbrella organization Pub-
P3G: Public
Population Project in
Genomics
lic Population Project in Genomics’ (P3G) was
established (96). P3G is a not-for-profit organi-
zation whose objective is to promote collabora-
tion between researchers in the field of popula-
tion genomics to undertake large-scale genomic
and epidemiologic research (96). Ethical guid-
ance is part of the P3G initiative (95). The Euro-
pean counterpart is the coordination action on
Promoting Harmonisation of Epidemiological
Biobanks in Europe, where ethical and societal
issues are also addressed (94). In practical terms,
for international collaborations, the most sen-
sitive issues include the width of the original
consent to secondary use of samples and data,
the definition of various levels of identifiabil-
ity (anonymization) (28, 69), which has implica-
tions for the ethical frameworks that are applied
to the biobank (28, 44), and the ethical over-
sight for international projects involving sev-
eral countries (12). Figure 2 shows the princi-
pal difference in meanings of “anonymized” in
the United States and in Europe. In the United
States, anonymized data and samples are those
where a link to identifying information exists
but the researcher has no access to the link-
ing key. Research with anonymized data has no
restrictions and may even not need specific eth-
ical approval (18, 44, 59, 90). In Europe, these
are considered as coded samples and data with
implications for their possible use (12, 19, 39).
This difference in approach may have impli-
cations for collaborations between Europe and
the United States. In the worst case, researchers
who are not aware of the different regulations
across countries might share data and samples
unlawfully in international collaborations (63).
Potential harm from biobank research. A
central issue in research ethics is avoidance
of harm to the participant (85, 89, 127). Al-
though no direct physical harm is expected from
biobank research, several other kinds of harm
should be considered (30, 48). Indirect physi-
cal harm could occur when a sample that was
collected in a clinical setting was exploited sub-
sequently for research purposes and no ma-
terial remains for future medical care. Non-
physical harm refers to social, psychological, or
www.annualreviews.org • Ethics of Nutrigenomics 453
A
n
n
u
. 
R
ev
. 
N
u
tr
. 
2
0
0
8
.2
8
:4
4
7
-4
6
7
. 
D
o
w
n
lo
ad
ed
 f
ro
m
 a
rj
o
u
rn
al
s.
an
n
u
al
re
v
ie
w
s.
o
rg
b
y
 U
n
iv
er
si
ty
 o
f 
N
ew
ca
st
le
 u
p
o
n
 T
y
n
e 
o
n
 0
2
/1
8
/0
9
. 
F
o
r 
p
er
so
n
al
 u
se
 o
n
ly
.
Figure 2
Communication barriers: the same terms are used with different meanings in various guidelines and journal articles (see 19, 90). COE,
Council of Europe Committee of Ministers; OHRP, U.S. Office for Human Research Protections. (Reprinted by permission from
Macmillan Publishers Ltd.: EMBO Reports, Elger BS, Caplan AL. 2006. Consent and anonymization in research involving biobanks:
differing terms and norms present serious barriers to an international framework. EMBO Rep. 7:661–66, copyright 2006.)
economical damage if sensitive information
such as diagnoses or genetic test results ends up
in inappropriate hands, i.e., if confidentiality is
broken (7). Nutrigenomics research could lead
to group harm due to stigmatization or prej-
udice if, for example, studies showed that cer-
tain sociodemographic or ethnic groups were at
higher risk of certain disorders or diseases be-
cause of a higher prevalence of a certain gene–
diet interaction (17, 30, 118). There may be
moral harm through storing or exchanging bio-
logical material that was not subject to informed
consent since it jeopardizes the subject’s au-
tonomy, privacy, and personal integrity. Moral
harm can also arise from lack of quality assur-
ance (42), nonefficient use of samples and data,
application of the wrong study design, or from
exclusion of certain groups from benefits that
arise from the research (30).
Ethical implications of anonymization. All
guidelines and legal frameworks allow unre-
stricted research with unlinked (irreversibly)
anonymized samples and data. This anonymiza-
tion is ethically critical because it excludes
the research participant from executing his or
her right of autonomy and self-determination
(112). When the link to identification data is
destroyed, the research participant cannot op-
pose certain kinds of research being undertaken
with his or her sample. Conversely, if partic-
ipants could benefit personally from knowl-
edge emerging from the research, it would
not be possible to advise the participant when
samples and data are unlinked (irreversibly)
anonymized. Anonymization may not protect
specific populations or social, ethnic, or reli-
gious groups from being stigmatized, which is
why ethical review is of importance (6, 11, 17,
30, 39, 44, 48, 118). One possible solution to
this problem is the establishment of a “sample
trustee” as a firewall between the researcher and
sample donor (7) or special routines for coding
and storage of samples with restricted access
to personal information (48). It should be the
norm for any emerging biobank to double code,
to store separately the clinical data, genetic in-
formation, and samples, and to restrict access
to key codes (7, 34, 39).
What Do Research
Participants Think?
In parallel to discussions among ethicists,
lawyers, and politicians about ethical implica-
tions of new technologies in the past decade,
empirical research has begun to reflect the opin-
ion of research participants. However, this kind
of research is still immature, and further sys-
tematic studies are needed. To date there have
been two kinds of studies: one asks partici-
pants hypothetically whether they would do-
nate a sample for genetic research and whether
they would agree to sample storage for future
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studies (64, 86, 105, 119), whereas the second
type analyzes given or declined consents by par-
ticipants of real studies (1, 16, 45, 47, 75, 79, 80,
108, 117). Although the majority of individuals
(71%–95%) consented to such research, agree-
ment to participate was lower among African
Americans (16, 45, 80). Among Jews, willing-
ness to participate was highest for conditions
that are preventable or treatable (105), which
would be a focus for nutrigenomics studies.
Higher education, good self-reported health,
having children, and positive history of genetic
disease among family or friends were associated
with greater willingness for sample donation in
a Swedish population (64). However, when at-
titudes and beliefs were included in the multi-
variate analysis, positive attitude toward genetic
research and trust in authorities’ ability to as-
sess the benefits and risks of genetic research
showed the strongest associations with willing-
ness to donate a sample (64).
Some studies on hypothetical participation
in studies focused on whether consent would
be required in future studies on stored sam-
ples and whether individuals want to be in-
formed of research results (86, 105, 119). Re-
spondents felt that the need for consent was
greater for clinically derived (versus research
derived) samples, but few would request such
consent when the name of the donor would not
be disclosed to the researcher. About 90% of
respondents would want to be informed about
results even if they were of uncertain clinical
relevance (119). Higher education was associ-
ated positively with a view that consent should
be necessary for future research projects (105).
In one American study of multilayer consent
forms with several options, about two-thirds of
participants in clinical trials did not complete
the consent form for future use of the samples,
possibly because they had problems with the
multilayer design. Of those who filled in the
consent form, 87% gave authorization for un-
limited future research (16). Malone et al. (75)
reported high assent rates for a multilayer con-
sent to storage (93.7%), future use for other
health problems (86.9%), and the repeated con-
tact by the physician for further participation
(84.3%). However, assent was also high to a
one-paragraph statement appended to the clini-
cal trial consent (89.4%). Those who participate
in studies are often a highly self-selected group
of people and ranged from 20% in a Jewish pop-
ulation (105) to 47%–49% in two Swedish and
one U.S. study (64, 86, 119). The proportion
of individuals who are not willing to consent
to sample collection, storage, and genetic re-
search may be rather high among the nonre-
spondents in those surveys. Nutrigenomics sci-
entists should be aware that their studies may be
biased to a certain extent by the sample of self-
selected participants (1), but this is a feature of
all research projects involving human subjects
and is not unique to nutrigenomics.
PERSONALIZED
NUTRITION—ETHICAL
AND SOCIAL IMPLICATIONS
The Idea of Personalized Nutrition
In the early days of nutritional genomics, hopes
were expressed that knowledge achieved in this
field could be used to modify plants and meat to
enhance their nutritional quality, through tradi-
tional methods as well as genetic modification
(25). However, this has not become a strong
trend, probably due to the negative reactions of
the general public, especially in Europe, toward
genetically modified food. Instead, nutrige-
nomics research has focused on other applica-
tions. Use of “omics” technologies aims at in-
creased knowledge on effects of food on human
metabolism, which may be the basis for more
informed general food advice for the public. A
major effort has been directed at understand-
ing genetically determined differences between
individuals, leading to the prospect for indi-
vidual genotype-based, tailor-made nutritional
advice—personalized nutrition (61, 62, 92).
Despite the great hopes expressed for per-
sonalization of nutrition based on genetic in-
formation, personalized nutrition is still con-
sidered premature. Whether this approach will
be successful ultimately will depend on the
predictive precision of the genetic information,
www.annualreviews.org • Ethics of Nutrigenomics 455
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PKU:
phenylketonuria
on the robustness of the gene-diet-disease rela-
tionship, and on the acceptance of the concept
by the public (57).
Observance
Targeted individual health advice can be a
strong motivator for behavior change. For ex-
ample, those with phenylketonuria (PKU), a
genetic disorder resulting in an inability to
metabolize phenylalanine, have to follow a life-
long strict diet that is low in phenylalanine
(71). With few exceptions, PKU sufferers ob-
serve these restrictions well, demonstrating that
well-founded and precise personal information
may be very effective. In another example, in
the Whitehall study by Rose et al. (100), those
whose examination had given evidence of ex-
ceptional risk received individualized advice on
why they in particular would benefit from stop-
ping smoking. More than 50% of them stopped
smoking, compared with approximately 10%
of those given routine antismoking advice
(99, 100).
Public Expectations
from Personalized Nutrition
Attitudes toward use of genetic information
seem to depend on the application area. Med-
ical and forensic applications are more easily
accepted than are genetic modifications of food
(74, 107). A recent Eurobarometer survey indi-
cates that the majority of respondents support
genetic testing for disease, but a sizeable mi-
nority is concerned about these medical uses of
genetic information (38). Recent surveys indi-
cate a strong consumer interest in the prospect
of genetic tests aimed at dietary advice with
identifiable health benefits, although concerns
have been expressed in relation to privacy and
the possibility of emotional reactions (76, 104).
The strongest audience seems to be among a
group actively seeking health information. It
has been suggested that one-third of consumers
will use genetic tests for personalized nutrition
(55). However, this interest needs to be seen in
a larger perspective.
Food, Health, and Well-Being
Food means much more than nutrition. Food
is enjoyment as well as cultural and personal
identity. A meal is a social event, an important
manifestation of the relationship with others.
This means that food is an important aspect of
human happiness and well-being, and not only
an instrument for health (49).
According to the WHO’s classical defini-
tion, “[h]ealth is a state of complete physical,
mental and social well-being and not merely
the absence of disease or infirmity” (122). This
is a far-reaching and ambitious understanding
of health, and it is unlikely that this can be
achieved except in rare circumstances. More
cautious definitions have been suggested by
health philosophers. For instance, Nordenfelt
(87) argued for a holistic theory of health de-
scribed as a person’s ability, in normal circum-
stances, to realize his vital goals. Two aspects of
this analysis of health stand out as important.
First, health is subjective rather than objective.
Second, health is not the only or final desire in
a person’s life.
According to a recent Eurobarometer sur-
vey, “being in good health” was ranked among
the top three items by three-quarters of the
population in the European Union member
states, and by two thirds in the acceding and
candidate countries. Other important values
were “sufficient income to meet my needs” and
“having family members who are there when
I need them.” The conclusion drawn in the
report is that “quality of life is obviously un-
derstood as a multi-dimensional concept de-
pending on several components rather than just
one particular ingredient of well-being” (4).
Philosophical analysis also invokes a broader
understanding of well-being than health only.
Well-being is described as informed and au-
tonomous endorsement of the conditions of
one’s life (110).
“The Unhealthy Quest for Health”
People in modern Western societies have
exceptional possibilities for healthy living.
Present society, as well as modern medicine,
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offers better opportunities than ever to avoid
health risks and to cure, retard, or mitigate
diseases. As a total effect of all societal, med-
ical, and individual efforts, the average life span
in Western societies has more than doubled
since the middle of the eighteenth century,
and it is still increasing. However, this im-
proved situation also brings greater hopes and
expectations.
Robert Crawford (23) understood our time
as characterized by exaggerated attention to
personal health—“elevating health to a super
value, a metaphor for all that is good in life.”
By introducing the term “healthism,” he wanted
to point out this societal phenomenon: an ide-
ology where maintaining health and avoiding
illness have become the supreme human val-
ues. Greenhalgh & Wessely (46) describe this
healthism as a modern cultural, mainly mid-
dle class, phenomenon. Some of its expressions
are strong health awareness, focus on lifestyle
choices, use of food supplements, and concern
about “unnatural” substances. A similar argu-
ment is offered in a recent report from the
U.K.’s Food Ethics Council, which suggests
that the government is reducing people’s auton-
omy because it assumes that consumers should
see food primarily as a means to health. “This
treats food like medicine and society like a hos-
pital,” according to the Food Ethics Council
(37). Geoffrey Rose (99) stated, “To be preoc-
cupied with health is unhealthy.”
Although such comments may be one-
sided or exaggerated, they point out that an
overemphasis on health may reduce percep-
tions of health as well as limit the realization of
well-being.
The Role of Genetic Testing
Genetic tests may be used for confirmatory di-
agnosis of specific genetic disorders as well as
for predictive testing for asymptomatic individ-
uals belonging to risk groups. In some cases,
such as PKU, the corresponding disease can
be effectively retarded by dietary intervention.
However, in the monogenic disorders, knowl-
edge of the phenotype is usually sufficient to
initiate dietary intervention because it measures
the expression of the disease. In complex poly-
genetic diseases such as diabetes and hyperten-
sion, the predictive value of a single genotype
is small compared with that of the family his-
tory of a person or other known risk factors (57,
115). However, especially with the expansion of
genome-wide scanning studies, understanding
of the genetic basis for polygenetic disorders
will increase, and genetic analysis may offer bet-
ter predictions of disease risk. This is particu-
larly important for diseases where the devel-
opment of the pathology and its complications
have long latency periods and are essentially ir-
reversible, such as in type 2 diabetes and osteo-
porosis (57).
“Opportunistic screening” refers to ad hoc
tests offered to those without symptoms or to
a test made upon request from an individual
patient without symptoms or known risk fac-
tors. Opportunistic screening is controversial
but is often accepted in society when it can
give predictive information on diseases that
may involve a heavy burden for the person
involved.
Should healthy people with no identified
risks who ask to have a genetic test be offered
that possibility? Most health professionals are
reluctant to agree to such requests because re-
spect for freedom of choice is not understood
to mean that all technically possible services
must be provided on request (120). Also, most
who attend screening examinations are seek-
ing not the discovery of hidden troubles, but
rather reassurance that they have no unusual
problems (99). At present, the evidence base
for genotype-specific dietary advice is very lim-
ited. This situation may change, but it seems
too early to estimate how autonomy and benef-
icence should be balanced against each other in
such a possible future.
Genetic Counseling in Connection
to Personalized Nutrition
Personalization of diet is not new, but genotyp-
ing as the basis for such advice opens a number
of new possibilities and problems. Counseling
www.annualreviews.org • Ethics of Nutrigenomics 457
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in a medical context is generally regarded to be
sensitive and personal, deserving careful treat-
ment, and considered a task for persons with
appropriate professional training. Genetic
counseling is often considered to be especially
demanding (20, 33, 120). The European Com-
mission comments on the current situation,
“Genetic testing will soon become part of ev-
eryday healthcare systems, and patients and
professionals will have to learn to make deci-
sions on the need for a test as well as under-
standing its consequences” (33). The essence of
their argument is that genetic exceptionalism is
not needed in order to argue that genetic infor-
mation should be handled with the same care as
any medical information and should be subject
to appropriate genetic counseling. As genetic
information has become more easily available,
this view has been challenged.
Following a test, the decision of what to eat
may be influenced by disease-prevention rea-
sons. However, dietary advice based on incon-
clusive or incomplete knowledge may result in
unnecessary restrictions in lifestyle and doubt-
ful health effects. Such considerations indicate
that dietary advice based upon genetic tests
should be handled with at least as much care
as genetic counseling in general.
When genetic information is collected and
used in formulating nutritional advice, a num-
ber of other well-known problems will reap-
pear: the confidentiality and right to privacy of
genetic information, the question of parental
authority in relation to testing of children, and
the risk of discrimination with respect to insur-
ance and employment (97).
Tests Directly Sold to the Public
A market has grown for promoting different
kinds of genetic analyses directly to public. The
U.K.’s Human Genetics Commission lists 26
companies (as of November 17, 2007) offering
genetic testing services via the Internet direct to
the consumer or via a nonmedical intermediary,
such as a pharmacist or alternative health prac-
titioner. These companies offer a wide range
of genetic tests of predispositions for diseases
and disorders. The majority of them market
tests combined with nutritional advice and, in
some cases, with nutritional supplements, and
at least one company offers biomarker assess-
ment tests. Most of them sell their tests directly
to consumers, and in some cases, the sale is com-
bined with optional or mandatory counseling
(51).
Recently, the marketing of genetic tests
to consumers for personalized nutrition and
lifestyle guidance received the attention of
the U.S. Government Accountability Office
(GAO), which investigated the legitimacy of
test claims in order to evaluate the current reg-
ulation. According to the GAO’s report (70),
all of the tests mislead consumers by mak-
ing predictions that are medically unproven
and meaningless. Some mislead consumers by
recommending costly dietary supplements that
may be unnecessary. The tests do not pro-
vide recommendations based on a unique ge-
netic profile, but instead common-sense recom-
mendations based on lifestyle information. The
GAO’s report concludes that the predictions
“may needlessly alarm consumers into think-
ing that they have an illness or that they need
to buy a costly supplement in order to prevent
an illness. Perhaps even more troubling, the
test results may falsely assure consumers that
they are healthy when this may not be the case”
(70).
How should this situation be handled? The
Council of Europe Working Party on Human
Genetics discusses the question of genetic tests
sold to the public (21). Different alternatives
are proposed, from the restrictive view, “Ge-
netic tests shall not be directly sold to the pub-
lic” to the liberal view, “Where the law per-
mits direct sale of genetic tests to the public,
there shall be adequate regulation, in particular
to ensure proper information and understand-
ing of the implications of the test the person
concerned.” The choice between these alterna-
tives is left open.
Castle et al. (13) agree that the efficacy of the
recommended dietary changes is not well docu-
mented but describe the information currently
generated as nonstigmatizing and nonsensitive,
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with mild informational impact and with mi-
nor potential harm. Others make the oppo-
site estimation. Joost et al. (57) describe the
current attempts to derive dietary recom-
mendations based on the genotypes of the
few single-nucleotide polymorphisms presently
known to be associated with complex diseases
as largely experimental, and emphasize the risk
of disappointment and adverse effects if tests
are introduced too early. Russo (101) describes
such tests as “genetic horoscopes.”
Today, many health consumers are better in-
formed than in the past about medical issues
because of better education and greater accessi-
bility to information through the Internet. But
the integrity and well-being of the consumers
who take genetic tests may still be at stake. Even
with counseling, and perhaps much more with-
out it, those involved may start worrying about
their health. This may be a result of the mere
focus on this kind of information, but the focus
only intensifies if the test results identify health
problems. However, according to Meijboom
et al. (81), “‘Sowing worries’ might be an ef-
fective marketing strategy.”
At present, the principles of beneficence
and nonmalfeasance are arguments that infor-
mation on results of genetic tests and that
counseling based upon such results should
be offered on a personal basis by specially
trained individuals because of the sensitivity
of the information as well as the possibility of
misunderstanding.
Individual or Population Approach?
Stronger efforts in promoting a healthy lifestyle
are often called for because of the increasing
prevalence of noncommunicable diseases (5).
However, the efficacy of an individual approach
to this problem is limited by the prevention
paradox (99). In most cases, the burden of ill
health comes more from the many who individ-
ually have a relatively low (inconspicuous) risk
than from the few who face an obvious prob-
lem. According to Rose (99), social and eco-
nomic factors are much more important than
genetics in explaining diseases and limit the ef-
fectiveness of an individual (high-risk) approach
to prevention. A similar assessment is made by
the Food Ethics Council (37), which claims that
many health problems can be better handled
by political actions such as regulation of mar-
keting, measures to tackle poverty, and health-
oriented reforms of agricultural subsidies. This
argument favors a population approach to pre-
vention advice.
In the current situation, the value of genet-
ically based nutritional advice for polygenetic
disorders is limited, and population-level ad-
vice may be more effective in improving pub-
lic health. Whether nutritional genomics will
lead to changes in population-wide health ad-
vice remains an open question (40). In some
cases, specific advice could be directed at popu-
lation groups in which the frequency of specific
alleles in the population is high. For instance,
in ethnic groups in which lactose intolerance is
very high, such as African American (79%) or
Asian (95%) (102), there is no need for genetic
tests prior to dietary advice to avoid lactose-
containing foods.
Products Fabricated
for Personalized Nutrition
The nutritional genomics approach has created
hopes that gene-based nutrition planning can
one day play a significant role in preventing
chronic disease, and industry has an interest in
using this knowledge for commercial purposes.
Some relevant questions in this respect include
(a) whether the scientific evidence base is suffi-
ciently strong to justify creating a special nutri-
tional product; (b) how personalized-nutrition
products can reach the correct target group;
(c) whether the advent of personalized-nutrition
products will encourage people to believe that
only some individuals need to adopt a healthy
diet or will create unwarranted or exaggerated
hopes and expectations; and (d ) how such a de-
velopment can be counteracted.
For the foreseeable future, the number of
people who have received personalized nutri-
tional advice based upon genetic tests is likely
to be fairly small and so the market for a new
www.annualreviews.org • Ethics of Nutrigenomics 459
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generation of “functional foods,” targeted to
these individuals, will be limited. In this situ-
ation, the food industry may be interested in
creating a larger market for each product by
developing the product and marketing it in such
a way that it is considered healthy not only for
people with a specific genetic constitution but
also for others. This is an undesirable devel-
opment because it may encourage the existing
tendency to healthism.
Another potential problem with this devel-
opment is that it will lead to medicalization of
the diet and normal healthy foods may be over-
looked. There is no industrial market for help-
ing people make healthy choices among exist-
ing natural products. The Food Ethics Council
comments, “Little money can be made by sell-
ing the fresh fruit and vegetables that form the
mainstay of healthy eating advice” (37).
An alternative trajectory may be offered by
the nutrigenomics approach in furthering un-
derstanding of normal metabolism and of how
normal foods interact with our genome to in-
fluence health. This might contribute to in-
creased public knowledge about healthy foods
as well as raise consciousness that healthy foods
matter.
Justice Questions
It is probable that the emerging market for
personalized nutrition will mainly be offered
to, afforded by, and used by a relatively small
group of proactive health information seekers
(55), which may increase existing health dis-
parities within industrialized countries as well
as between these and the developing countries.
This has been described as still another example
of the “health genomics divide” (106), a selec-
tive implementation of biotechnologies. Some
consider this divide to be mainly a moral prob-
lem (41) and have called instead for use of nu-
trigenomics to reduce global health inequities
(13).
As an alternative to individualized nutrition,
population-based research on the role of race
and genetics in health disparities has been ini-
tiated (36). The epidemic of noncommunicable
diseases is growing (5) due to adverse changes
in dietary patterns and reductions in physical
activity, but it is also recognized that genetic
variability is likely to play a role in determin-
ing susceptibility. The WHO speculated on tar-
geted dietary advice for subgroups as a pre-
vention strategy in developing countries (124,
125). However, this is not considered feasible
at present because the multiple causes of com-
plex diseases are not yet well understood, and
changes in diet and lifestyle seem to be larger
causal factors than is genetic susceptibility.
CONCLUSIONS
Nutrigenomics is a rapidly expanding field of
research with ethical issues in respect to both
protection of research participants and soci-
ety’s interest in the prevention and treatment
of common diseases by nutritional measures.
The same four principles designed to protect
research participants, i.e., autonomy, benefi-
cence, nonmalfeasance, and justice, apply in
nutrigenomics as well as in other types of
biomedical research. However, the novel issues
with respect of nutrigenomics research include
(a) how to handle genotypic information that
has no, or poorly understood, implications
for the health or well-being of the research
participant, and (b) the use of biobanks, es-
pecially when this includes sharing of data
and/or samples internationally. Contrary to
the usual position that research participants
should be provided with personal data arising
from the investigation, there is a case for not
giving consenting participants “their” geno-
typic information. For biobanks, there are is-
sues around whether, and how, volunteers can
withdraw consent and the future use of stored
samples.
Research on diet–gene interactions and, in
particular, on the relationships between geno-
type, dietary exposure, and disease risk is a hot
topic internationally. However, the scientific
evidence base for the role of interactions be-
tween specific genotypes and components of
the diet in the development of polygenic dis-
eases is fragmentary and, in our view, is not
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yet sufficiently robust to justify genetic testing
as the basis for nutritional counseling (person-
alized nutrition). It is probable that a major
benefit of nutrigenomics research will be an
enhanced understanding of the mechanisms
through which dietary factors interact with the
genome to influence gene expression and cell
function and, ultimately, health. The outcomes
of such research may have societal benefits
in increased public knowledge about healthy
foods and raised awareness that healthy foods
matter.
SUMMARY POINTS
1. Ethical considerations in human nutrigenomics include both research ethics and the
societal implications of applications of this emerging science.
2. From a research perspective, the ethical issues are in the areas of informed consent,
genotype information, biobanks, and the use and exchange of samples.
3. The two most ethically challenging aspects of nutrigenomics science are the use and
communication of genetic information and the conduct of large-scale, population-based
studies in an international context.
4. International legislation and regulations impinging on nutrigenomics research vary be-
tween countries with complex (and some unresolved) issues for transnational collabora-
tions.
5. The benefits of nutrigenomics research for society in terms of improved health care or
disease prevention remain unclear.
6. One much-hyped potential application of nutrigenomics research is personalized nutri-
tion, but at present, the evidence base for genotype-specific dietary advice is very limited.
7. Promotion of the concept of personalized nutrition may have unintended and undesirable
consequences, including medicalization of food choice and eating behavior.
8. The major societal benefit from nutrigenomics research is likely to be enhanced under-
standing of how food components and food interact with the human genome to influence
health.
FUTURE ISSUES
1. What are the optimum approaches to international harmonization and standardization
of legislation and regulations affecting nutrigenomics research?
2. How can the implementation of research ethics regulations in nutrigenomics research
be an instrument to respect the integrity of research subjects and not only a bureaucratic
act?
3. How can new technologies and media such as the Internet be used to enhance commu-
nication with research participants to address better the issue of informed consent?
4. Can nutrigenetic information at the individual level be used in the context of prevention
of diseases and health care?
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